<DOC>
	<DOCNO>NCT00586274</DOCNO>
	<brief_summary>While stem cell transplantation proven effective mean treat wide variety disease involve hematopoietic stem cell progeny , shortage donor prove major impediment wide application approach . Until recently , MHC identical donor could use safety . Such donor originally sibling closely related family member . Over past decade , growth allogeneic donor panel allow transplantation stem cell obtain volunteer donor panel . While possible obtain HLA identical unrelated donor stem cell approximately 75 % individual Northern European background , situation ethnic group much less satisfactory . Even match donor found , elapsed time commence search collect stem cell usually exceed three month , delay may doom many needy patient . Hence considerable interest making use HLA haploidentical family donor . Most individual first-degree relative would suitable protocol . Fanconi anemia ( FA ) autosomal recessive disorder characterize development progressive aplastic anemia usually evident age seven year often associate various diverse congenital anomaly short stature , microcephaly , radial anomaly , horseshoe kidney , cafe au lait spot . This study determine number donor lymphocytes give recipient haploidentical stem cell transplant Fanconi anemia depletion recipient-reactive T lymphocytes ex-vivo treatment fix dose RFT5-dgA immunotoxin , result rate Grade III/IV GVHD &lt; / = 25 % .</brief_summary>
	<brief_title>Use Rft5-Dga Deplete Alloreactive Cells Pts With Fanconi Anemia After Haploidentical SCT</brief_title>
	<detailed_description>Patients receive haplo-identical stem cell transplant on-going study `` CD45 ( YTH-24 YTH-54 ) CD52 ( Campath 1H ) Monoclonal Antibody Conditioning Regimen Allogeneic Donor Stem Cell Transplantation Patients Fanconi Anemia '' ( H-9938 IND # 7233 ) become eligible receive allodepleted T Cells follow engraftment . What follow summary treatment plan include initial transplant phase well generation infusion allodepleted T cell . Preparative Regimen Patients Fanconi Anemia : The study open patient receive haploidentical PBSCT MAFIA protocol patient fail engraft receive second haploidentical transplant alternate condition consist ATG , Fludarabine , TBI ( 450cGY single dose ) Cytoxan . In Outline MAFIA conditioning ( primary condition regimen ) Day 8 Campath 1H 10mg iv 4hr Fludarabine 30 mg/m2 7 Campath 1H 10mg iv 4hr Fludarabine 30 mg/m2 6 Campath 1H 10mg iv 4hr Fludarabine 30 mg/m2 5 YTH 24/54 400ug/kg 6 hr Fludarabine 30 mg/m2 - 4 YTH 24/54 400ug/kg 6 hr Fludarabine 30 mg/m2 - 3 YTH 24/54 400ug/kg 6 hr - 2 YTH 24/54 400ug/kg 6 hr - 1 Rest - 0 CD34-selected PBSC infusion Stem Cell Infusion : One day completion pretransplant conditioning therapy ( day 0 ) , CD34+ cell infused central venous catheter outline CAGT SOPs . This study begin dose T cell know cause GvHD even haploidentical recipient , even T cell administer first allodepleted . Dose escalation follow traditional method , result become available used determine subsequent dose level continual reassessment method . Initially , 2 patient enter begin dose level 1 . Each every patient receive three additional injection T cell dose , monthly interval , provide evidence grade 2 high GVHD , total T cell number &gt; 1000/ul . Dose level -1 ( 1 x 10^3 T cells/Kg ) ; Dose level 1 ( 1 x 10^4 T cells/Kg ) ; Dose level 2 ( 1 x 10^5 T cells/Kg ) ; Dose level 3 ( 1 x 10^6 T cells/Kg ) ; Dose level 4 ( 5 x 10^6 T cells/Kg )</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>At time eligibility infusion allodepleted T cell patient must satisfy criterion : Patients Fanconi anemia age severe aplasia ( evidenced hypocellular bone marrow ) lack suitable conventional relate ( i.e . 5/6 6/6 relate ) 5/6 6/6 unrelated donor least 2 3 following : ) ANC &lt; 500/mm3 , b ) reticulocytes &lt; 1 % c ) platelets &lt; 50,000/mm3 Diagnosis Fanconi anemia confirm study peripheral blood bone marrow sensitivity mitomycinC DEB prior stem cell transplant . Have receive related haploidentical CD34selected peripheral blood stem cell transplant evidence full partial hematopoietic donor chimerism ( &gt; 50 % ) peripheral blood . Patients life expectancy ( &lt; 6 week ) limit disease FA Patients active GVHD &gt; / = Grade II Patients severe renal disease ( i.e . creatinine great 3 X normal age ) Patients severe hepatic disease ( direct bilirubin great 3ug/dl SGPT great 500ug/dl ) Patients severe intercurrent infection Lansky scale &lt; 60 Karnofsky &lt; 60</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Anemia</keyword>
	<keyword>Fanconi</keyword>
</DOC>